Application of ALK targeting tyrosine kinase inhibitors such as crizotinib [9], ceritinib [10], alectinib [11], and brigatinib [12], have largely improved prognosis as well as life quality of ALK fusion-positive NSCLC patients. This evidence concerns the gene ALK and non-small cell lung carcinoma.